MaxSimil and Vitamin K2: Determining Their Bioavailability

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 29, 2019

Primary Completion Date

November 23, 2019

Study Completion Date

March 31, 2020

Conditions
Healthy
Interventions
DIETARY_SUPPLEMENT

Omega-3 + vitamin K2 (TG form of omega-3)

"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."

DIETARY_SUPPLEMENT

Omega-3 + vitamin K2 (EE form of omega-3)

"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."

DIETARY_SUPPLEMENT

Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]

"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."

Trial Locations (1)

J1H4C4

Melanie Plourde, Sherbrooke

All Listed Sponsors
collaborator

Samuel Fortin, SFC pharma and associate professor UQAR

UNKNOWN

lead

Université de Sherbrooke

OTHER

NCT03897660 - MaxSimil and Vitamin K2: Determining Their Bioavailability | Biotech Hunter | Biotech Hunter